---
title: Bispecific T-Cell Engager (BiTE)
url: "https://www.yyhmedical.com/en/guide/technology/bite-therapy"
type: MedicalWebPage
inLanguage: en-US
---

# Bispecific T-Cell Engager (BiTE)

> Bispecific T-cell engagers (BiTEs) are a type of immunotherapy designed to bind to both cancer cells and T cells.

## Overview

Bispecific T-cell engagers (BiTEs) are a type of immunotherapy designed to bind to both cancer cells and T cells. One part recognizes a specific antigen on the cancer cell, while the other typically binds to CD3 on T cells, bringing the two cells together and activating the T cell to attack the cancer cell.

  

BiTE is one type of bispecific antibody technology and is used mainly in certain blood cancers, including acute lymphoblastic leukemia and multiple myeloma. Other types of bispecific antibodies are also used in cancer treatment, and not all bispecific antibodies are BiTEs.

## Indications

BiTEs and other T-cell–engaging bispecific antibodies are used mainly for selected blood cancers. Whether they are appropriate depends on the cancer type, stage of treatment, previous therapies, and the presence of a relevant target on the cancer cells.

  

For example, CD19-directed T-cell engagers may be used in certain patients with B-cell acute lymphoblastic leukemia. BCMA-directed bispecific antibodies are used in some patients with multiple myeloma, while CD20-directed bispecific antibodies are available for certain lymphomas.

  

Indications and treatment timing vary by drug and disease, so treatment needs to be individualized.

## Treatment Process

Bispecific antibodies are drug-based treatments and, unlike CAR-T cell therapy, do not require a patient's T cells to be collected and genetically modified before treatment. Once administered, these drugs can engage the patient's own T cells to attack cancer cells.

  

Depending on the drug, treatment may be given by intravenous infusion or subcutaneous injection. Some therapies use step-up dosing at the beginning of treatment to reduce the risk of cytokine release syndrome and other early adverse reactions.

  

During treatment, patients undergo regular blood tests and disease assessments and are monitored closely for infection, cytokine release syndrome, and neurologic side effects.

## Risks and Complications

Cytokine release syndrome (CRS) is an important adverse event associated with T-cell–engaging bispecific antibodies. Fever is common, while more significant reactions may include low blood pressure or low oxygen levels. CRS occurs most often early in treatment.

  

Other possible side effects include infections, low white blood cell or neutrophil counts, anemia, low platelet counts, and neurologic adverse events. The type and frequency of side effects vary among individual drugs.

  

Some bispecific antibodies targeting plasma cell–related antigens may also affect normal immune function and increase the risk of infection. Infection prevention, immunoglobulin monitoring, and other supportive measures may therefore be needed during treatment.

## Content attribution (YMYL)
- Author:
- Medically reviewed by:
- Last reviewed:
- First published:

> 

---
Original (HTML):https://www.yyhmedical.com/en/guide/technology/bite-therapy
This is a clean Markdown mirror for large language models; the original page is authoritative.